|
業務類別
|
Biotechnology |
|
業務概覽
|
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3. |
| 公司地址
| 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478 |
| 電話號碼
| +1 713 489-8654 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tvarditherapeutics.com |
| 員工數量
| 12 |
| Dr. Imran Nizamudin Alibhai, PhD |
Director and Chief Executive Officer |
美元 620.00K |
23/04/2026 |
| Dr. John Saewook Kauh, M.D. |
Chief Medical Officer |
美元 500.00K |
23/04/2026 |
| Mr. Avi Daniel Conn, J.D. |
Chief Financial Officer |
美元 450.00K |
23/04/2026 |
| Mr. Stephen Paul O’Brien, C.P.A. |
Principal Accounting Officer, Vice President, Finance and Corporate Controller |
-- |
31/03/2026 |
|
|
| Mr. Wallace L. Hall, Jr |
Independent Director |
23/04/2026 |
| Mr. Michael Stephen Wyzga |
Independent Director |
23/04/2026 |
| Dr. Imran Nizamudin Alibhai, PhD |
Director and Chief Executive Officer |
23/04/2026 |
| Mr. Sujal Shah |
Chairman of the Board |
23/04/2026 |
| Dr. Susan Shiff, M.B.A.,PhD |
Independent Director |
23/04/2026 |
| Ms. Cynthia Smith |
Independent Director |
23/04/2026 |
|
|
|
|
